COST-EFFECTIVENESS OF ANTIPSYCHOTIC DRUGS FOR FIRST- AND SECOND-LINE TREATMENT OF SCHIZOPHRENIA IN BRAZIL

Author(s)

Santos A, Noronha KVMDS, Andrade MV, Ruas CM
Universidade Federal de Minas Gerais, Belo Horizonte, Brazil

Presentation Documents

OBJECTIVES

Considering the low effectiveness of the treatment of schizophrenia and the potential high cost of an inadequate choice, this study aims to conduct an economic evaluation of the list of subsidized antipsychotic drugs in Brazil to allow an adequate choice of pharmacotherapy for the patient and the financial reality of the Brazilian public health system (SUS).

METHODS

A three-year Markov model with quarterly cycles was developed in TreeAge Pro® 2009 to assess the cost-effectiveness of the first- and second-line treatment of schizophrenia with six antipsychotic drugs - haloperidol, chlorpromazine, risperidone, quetiapine, ziprasidone and olanzapine. Clozapine was indicated as third-line treatment. Outcomes were measured in quality-adjusted life years (QALYs). The perspective of the public health system was adopted. BRL values were converted to PPP-USD using OECD conversion rates.

RESULTS

42 different combinations of drugs were evaluated. Only six strategies were not absolutely dominated and, of these, only three were not extendedly dominated. These were chlorpromazine/olanzapine ($7,063 USD; 1.135 QALY), chlorpromazine/risperidone ($8,132 USD; 1.988 QALY) and olanzapine/risperidone ($8,350 USD; 2.055 QALYs). Incremental cost-effectiveness ratios (ICERs) were generally low (chlorpromazine/olanzapine vs. chlorpromazine/risperidone: ICER=1,253 USD/QALY; chlorpromazine/risperidone vs. olanzapine/risperidone ICER=3,254 USD/QALY). Compared to any proposed cost-effectiveness threshold for Brazil, the strategy olanzapine/risperidone would be considered cost-effective.

CONCLUSIONS

Since olanzapine and risperidone have reasonably different safety profiles and comparable effectiveness, this strategy should be recommended, respectively, for first- and second-line treatment of patients with schizophrenia, who do not have shown previous contraindications to the substances, in SUS.

Conference/Value in Health Info

2019-09, ISPOR Latin America 2019, Bogota, Colombia

Value in Health Regional, Volume 20S (October 2019)

Code

PMH6

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

Mental Health

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×